Search results for "Long-Term Outcome"

showing 10 items of 19 documents

Outcomes of Liver Transplant for Adults With Wilson’s Disease

2020

Wilson's disease (WD) is a rare genetic disorder with protean manifestations. Even if liver transplantation (LT) could represent an effective therapeutic option for patients with end-stage liver disease, it has remained controversial in the presence of neuropsychiatric involvement. This study aimed to examine the frequency of adult LT for WD in Italy, focusing on the disease phenotype at the time of LT. A retrospective, observational, multicenter study was conducted across Italy exploring the frequency and characteristics of adults transplanted for WD between 2006 and 2016. A total of 29 adult WD patients underwent LT during the study period at 11 Italian LT centers (accounting for 0.4% of …

AdultMalewilson disease liver transplantationmedicine.medical_specialtymedicine.medical_treatmentwilson diseaseDisease030230 surgeryLiver transplantationSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineHepatolenticular DegenerationInternal medicineAcute on chronic liver failuremedicineHumansRetrospective StudiesTransplantationHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAWilsonGenetic disorderPatient survivalmedicine.diseaseLong-term outcomeLiver TransplantationNeuropsychiatric symptomsWilson's diseaseTreatment OutcomeItalyCirrhosisMulticenter studyAcute on chronic liver failure; Cirrhosis; Long-term outcome; Neuropsychiatric symptomsFemale030211 gastroenterology & hepatologySurgerybusinessNeurological impairmentLiver Transplantation
researchProduct

Incidence and Clinical Impact of Right Ventricular Involvement (Biventricular Ballooning) in Takotsubo Syndrome: Results From the GEIST Registry

2021

Background: The short- and long-term prognosis of Takotsubo syndrome (TTS) presenting with right ventricular (RV) involvement remains poorly understood. Research Question: What is the incidence and clinical outcome of RV involvement in TTS? Study Design and Methods: This study analyzed 839 consecutive patients with TTS (758 female subjects and 81 male subjects) in a multicenter registry. RV involvement was defined as wall motion abnormality of the RV free wall, with or without apical involvement. The median long-term follow-up was 2.1 years (interquartile range, 0.3-4.5 years). The primary outcome was in-hospital and out-of-hospital all-cause mortality. The secondary end point was a composi…

Aged 80 and overMaleIncidenceVentricular Dysfunction Rightshort- and long-term outcomeShock CardiogenicArrhythmias CardiacPulmonary EdemaMiddle AgedPrognosisVentricular Dysfunction Leftright ventricular involvementTakotsubo CardiomyopathyThromboembolismHumansFemaleHospital MortalityRegistriesMortalityTakotsubo syndromeAged
researchProduct

Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort

2021

[Background] Lower levels of education have been associated with the development of psychosis. Investigating educational achievement in the first episode of psychosis (FEP) patients may shed light on the origins of the alterations and on the variability of outcomes in psychotic disorders.

First episodemedicine.medical_specialtyPsychosisIntelligence quotientbusiness.industryAttendanceNeuropsychologyCognitionmedicine.diseaseFirst-episode psychosis030227 psychiatryEducation03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineCohortmedicineLong-term outcomesPsychiatrybusinessNeurocognitiveNeurocognition030217 neurology & neurosurgeryApplied Psychology
researchProduct

Sepsis at ICU admission does not decrease 30-day survival in very old patients : a post-hoc analysis of the VIP1 multinational cohort study

2020

AbstractBackgroundThe number of intensive care patients aged ≥ 80 years (Very old Intensive Care Patients; VIPs) is growing. VIPs have high mortality and morbidity and the benefits of ICU admission are frequently questioned. Sepsis incidence has risen in recent years and identification of outcomes is of considerable public importance. We aimed to determine whether VIPs admitted for sepsis had different outcomes than those admitted for other acute reasons and identify potential prognostic factors for 30-day survival.ResultsThis prospective study included VIPs with Sequential Organ Failure Assessment (SOFA) scores ≥ 2 acutely admitted to 307 ICUs in 21 European countries. Of 3869 acutely admi…

INTENSIVE-CARE-UNITSurvivalHSJ UCICritical Care and Intensive Care Medicinesurvival analysislaw.inventionsepsisSeverity of illne0302 clinical medicineLONG-TERM OUTCOMESoverlevingsanalyselawMedicine and Health SciencesEPIDEMIOLOGYIntensive care; Mortality; Outcome; Sepsis; Severity of illness; Survival; Very old030212 general & internal medicineProspective cohort studyELDERLY-PATIENTSOutcomeddc:617PATIENTS AGED 80lcsh:Medical emergencies. Critical care. Intensive care. First aidVery OldIntensive care unitSOFA scoremedicine.symptomCRITICALLY-ILL PATIENTSWITHDRAWALhormones hormone substitutes and hormone antagonistsmedicine.medical_specialtySepsiVery oldelderly patientsSeverity of illnessNOSepsis03 medical and health sciencessterfteSepsisInternal medicineIntensive careSeverity of illnessmedicineMortalityFRAILTYbusiness.industrySeptic shockResearchSEPTIC SHOCKOrgan dysfunctionIntensive Care030208 emergency & critical care medicinelcsh:RC86-88.9oudere patiëntenmedicine.diseaseIntensive carebusiness
researchProduct

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease

2020

Background & Aims Patients with nonalcoholic fatty liver disease (NAFLD) have an increased risk for liver-related complications, such as decompensation, hepatocellular carcinoma (HCC), and death; the severity of liver fibrosis and metabolic comorbidities are the main risk factors. A single nucleotide polymorphism in patatin-like phospholipase domain-containing-3 (PNPLA3) gene is associated with higher prevalence of liver damage and HCC, but there are no data from prospective studies of outcomes of patients with this polymorphism. We investigated whether the common rs738409 variant in PNPLA3 gene associates with the occurrence of liver-related events and death in a large cohort of patients w…

Liver Cancermedicine.medical_specialtyCirrhosisCarcinoma HepatocellularGenotypeGastroenterologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansDecompensationGenetic Predisposition to DiseaseProspective StudiesProspective cohort studyHepatologyProportional hazards modelbusiness.industryPrognostic FactorRisk FactorHazard ratioLiver NeoplasmsGastroenterologyMembrane ProteinsLong-Term OutcomeLipasemedicine.disease030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologybusinessLiver cancer
researchProduct

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.

2016

Clearance of hepatitis C virus (HCV) via antiviral treatment changes the course of liver disease. We evaluated the benefit of sustained virologic response (SVR) in patients with HCV and cirrhosis without (stage 1) and with (stage 2) esophageal varices (EV).We performed a prospective cohort study of 444 patients with HCV and compensated cirrhosis (218 with stage 1 and 226 with stage 2 disease) treated with peg-interferon and ribavirin from June 2001 through December 2009 at the University of Palermo, Italy and followed for a median of 7.6 years (range, 1-12.6 years). We used Cox regression analysis to identify variables associated with appearance or progression of EVs, development of hepatoc…

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepacivirusEsophaguGastroenterologyPolyethylene GlycolsLiver diseasechemistry.chemical_compound0302 clinical medicineEsophageal varicesProspective StudiesProspective cohort studyHazard ratioGastroenterologyvirus diseasesMiddle AgedPortal PressureHepatitis CRecombinant ProteinsIntention to Treat AnalysisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyInterferon alpha-2Lower riskEsophageal and Gastric VaricesAntiviral Agents03 medical and health sciencesInternal medicineHypertension PortalRibavirinmedicineHumansAgedProportional Hazards ModelsHepatologybusiness.industryRibavirinBleedingInterferon-alphaLong-Term Outcomemedicine.diseasedigestive system diseaseschemistrybusinessFollow-Up StudiesGastroenterology
researchProduct

Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis

2019

Abstract Objectives In patients with LN, clinical and histological responses to treatment have been shown to be discordant. We investigated whether per-protocol repeat kidney biopsies are predictive of LN relapses and long-term renal function impairment. Methods Forty-two patients with incident biopsy-proven active proliferative (class III/IV±V) LN from the database of the UCLouvain were included in this retrospective study. Per-protocol repeat biopsies were performed after a median [interquartile range (IQR)] time of 24.3 (21.3–26.2) months. The National Institutes of Health activity index (AI) and chronicity index (CI) scores were assessed in all biopsies. Results Despite a moderate corre…

MaleBiopsy030232 urology & nephrologyKidneyGastroenterologychemistry.chemical_compound0302 clinical medicinesystemic lupus erythematosusRecurrenceInterquartile rangePharmacology (medical)Proteinuriamedicine.diagnostic_testHazard ratioPrognosisLupus NephritisProteinuriaKidney TubulesCreatinineDisease ProgressionhistopathologyFemaleRenal biopsymedicine.symptomRituximabImmunosuppressive AgentsAdultlong-term outcomemedicine.medical_specialtyRenal functionMethylprednisoloneYoung Adult03 medical and health sciencesrenal biopsyRheumatologyInternal medicineBiopsymedicineHumansImmunologic FactorsCyclophosphamideGlucocorticoidsProportional Hazards ModelsRetrospective Studieslupus nephritisrepeat biopsy030203 arthritis & rheumatologyCreatininebusiness.industryrenal functionMycophenolic AcidchemistryPulse Therapy DrugHistopathologybusinessRheumatology
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Observed and relative survival and 5-year outcomes of patients discharged after acute myocardial infarction: the nationwide AMI-PL database.

2020

Background: Long‑term follow‑up data from a large Polish acute myocardial infarction (AMI‑PL) database are still unavailable. Aims: This study aimed to assess the 5‑year outcomes of patients discharged after hospitalization for AMI in Poland in relation to age. Methods: The studywas based on the nationwide AMI‑PL registry including data on the management and long‑term outcomes of all patients admitted to hospitals with AMI (codes I21–I22 according to the International Classification of Diseases and Related Health Problems, 10th Revision [ICD ‑10]), derived from the database of the obligatory healthcare payer in Poland.The current analysis included all patients after AMI who were discharged …

MaleMEDLINEMyocardial InfarctionDischarged alive030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineOlder patientsRisk FactorsmedicineHumansIn patientcardiovascular diseasesMyocardial infarctionAgedAged 80 and overnon-ST-segment elevation myocardial infarctionDatabaseRelative survivalbusiness.industryrelative survivalMiddle Agedmedicine.diseasePatient DischargeST-segment elevation myocardial infarctionHospitalizationHeart failurepopulation-based databaseFemalePolandCardiology and Cardiovascular MedicineIndex hospitalizationbusinesscomputerlong-term outcomesKardiologia polska
researchProduct

Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease.

2009

Objective: To investigate long-term outcomes of unprotected left main coronary artery (ULMCA) disease treatment using drug-eluting stents (DES). Background: In several studies, DES implantation in ULMCA appeared safe and effective at mid-term; however, to date, there is limited long-term data. Methods: All consecutive patients undergoing sirolimus- or paclitaxel-eluting stent implantation in ULMCA disease at a single institution were evaluated. The primary endpoint was long-term major adverse cardiac events (MACE) defined as cardiac death, nonfatal myocardial infarction, or target lesion revascularization (TLR). Stent thrombosis (ST), according to Academic Research Consortium definitions, w…

Malemedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentCoronary Artery DiseaseCoronary AngiographyRestenosisRecurrenceInternal medicineLong-term outcomes.medicineClinical endpointHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionSurvival rateAgedProportional Hazards ModelsSirolimusChi-Square Distributionbusiness.industryHazard ratioEuroSCOREDrug-Eluting StentsGeneral MedicineLeft main coronary arterymedicine.diseaseSurgeryTreatment OutcomeDrug-eluting stentCardiologyFemaleDrug-eluting stentCardiology and Cardiovascular MedicinebusinessMaceFollow-Up StudiesCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct